H.C. Wainwright initiated coverage of Tetraphase Pharmaceuticals (NASDAQ:TTPH) with a “buy” rating and $15 price target. The stock closed at $6.88 on July 10.Read More
Roth Capital Partners upgraded Cempra (NASDAQ:CEMP) to “buy” and maintained its $8 price target after the company announced positive Phase 3 results in the first of two skin infection (ABSSSI) studies with Taksta. The stock was quoted at $4.20 near midday on Feb. 27.Read More
Ladenburg Thalmann slashed its price target for Aradigm (NASDAQ:ARDM) to $7.50 from $26 but maintained its “buy” rating after the company reported mixed top-line Phase 3 results for Pulmaquin for the treatment of non-cystic fibrosis bronchiectasis (NCF-BE).Read More
Ocular Therapeutix (NASDAQ:OCUL) has completed an end-of-Phase 2 review with the FDA for its sustained release travoprost product candidate, OTX-TP, for the treatment of glaucoma and ocular hypertension and intends to initiate the first of two Phase 3 clinical trials during the third quarter of 2016.
The FDA has stated that it agrees with the overall Phase 3 clinical development program proposed by Ocular in its briefing package submitted to the FDA.Read More